Preferred Name | Zileuton | |
Synonyms |
N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea (+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea ZILEUTON Zileuton Zyflo zileuton |
|
Definitions |
A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04) |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C26667 |
|
Accepted_Therapeutic_Use_For |
Prevention and Chronic treatment of Asthma |
|
ALT_DEFINITION |
A substance that is used to prevent asthma symptoms and that is being studied in the prevention of lung cancer. It belongs to the family of drugs called leukotriene blockers. |
|
CAS_Registry |
111406-87-2 |
|
CHEBI_ID |
CHEBI:10112 |
|
Chemical_Formula |
C11H12N2O2S |
|
code |
C26667 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
Contributing_Source |
CTRP FDA |
|
DEFINITION |
A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04) |
|
Display_Name |
Zileuton |
|
FDA_UNII_Code |
V1L22WVE2S |
|
FULL_SYN |
N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea (+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea ZILEUTON Zileuton Zyflo zileuton |
|
label |
Zileuton |
|
Legacy Concept Name |
Zileuton |
|
NCI_Drug_Dictionary_ID |
285649 |
|
NSC Number |
730712 |
|
PDQ_Closed_Trial_Search_ID |
285649 |
|
PDQ_Open_Trial_Search_ID |
285649 |
|
Preferred_Name |
Zileuton |
|
prefixIRI |
Thesaurus:C26667 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0081408 |
|
subClassOf |